HENGRUI PHARMA has announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for the SHR-6914 injection. The clinical trial is scheduled to commence in the near future.

The SHR-6914 injection is an innovative anti-tumor drug independently developed by the company, intended for the treatment of prostate cancer. According to available information, there are currently no similar drugs approved for marketing either domestically or internationally.

To date, the cumulative research and development investment for the SHR-6914 injection project amounts to approximately 29.2 million yuan, which has not been audited.